Keywords: gsk, requip, fares, well, vs, schwarz, neupro
GSK's ReQuip fares well vs Schwarz' Neupro
Article | 17 April 2006
UK pharmaceutical major GlaxoSmithKline says that its dopamine agonist ReQuip (ropinirole) was superior to Germany-based Shwarz Pharma's rotigotine, in the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
